Skip to main content
NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
28.72
-1.73 (-5.68%)
Apr 28, 2026, 4:00 PM EDT - Market closed

NAMS Revenue

In the year 2025, NewAmsterdam Pharma Company had annual revenue of $22.50M, down -50.61%. NewAmsterdam Pharma Company had revenue of $32.00K in the quarter ending December 31, 2025, a decrease of -99.75%.

Revenue (ttm)
$22.50M
Revenue Growth
-50.61%
P/S Ratio
146.74
Revenue / Employee
$225,030
Employees
100
Market Cap
3.30B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202522.50M-23.06M-50.61%
Dec 31, 202445.56M31.47M223.37%
Dec 31, 202314.09M-88.60M-86.28%
Dec 31, 2022102.69M--
Dec 31, 2021---
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
ACADIA Pharmaceuticals 1.07B
Telix Pharmaceuticals 803.79M
Catalyst Pharmaceuticals 588.99M
Travere Therapeutics 490.73M
Arcus Biosciences 247.00M
Tango Therapeutics 62.38M
Alumis 24.05M
Revenue Rankings

NAMS News

More News